Moderna Inc (NASDAQ:MRNA) price on current trading day, fall -3.36% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $33.60.
A look at the stock’s price movement, the level at last check in today’s session was $34.77, moving within a range at $33.54 and $34.95. The beta value (5-Year monthly) was 1.69. Turning to its 52-week performance, $170.47 and $31.94 were the 52-week high and 52-week low respectively. Overall, MRNA moved -19.67% over the past month.
Moderna Inc’s market cap currently stands at around $12.93 billion, with investors looking forward to this quarter’s earnings report slated for in February.
Analysts have a consensus estimate of 1.06B for the company’s revenue for the quarter, with a low and high estimate of 861.12M and 1.6B respectively. The average forecast suggests down to a -62.27% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 3.25B, representing a -52.58% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that MRNA is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
17 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 3 analyst(s) rate the stock as a Hold, 12 recommend MRNA as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 2 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
MRNA’s current price about -15.69% and -19.82% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 33.71, while 7-day volatility ratio is 7.39% and 6.19% in the 30-day chart. Further, Moderna Inc (MRNA) has a beta value of 1.60, and an average true range (ATR) of 2.91. Analysts have given the company’s stock an average 52-week price target of $77.5, forecast between a low of $55 and high of $238. Looking at the price targets, the low is -63.69% off recent price level in today’s trading while to achieve the yearly target high, it has to move -608.33%. Nonetheless, investors will most likely welcome a -130.65% jump to $77.5 which is the analysts’ median price.
If we refocus on Moderna Inc (NASDAQ:MRNA), historical trading data shows that trading volumes averaged 12.47 over the past 10 days and 8.86 million over the past 3 months. The company’s latest data on shares outstanding shows there are 385.00 million shares.
The 10.82% of Moderna Inc’s shares are in the hands of company insiders while institutional holders own 67.51% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 37.85 million on 2024-12-31, giving us a short ratio of 4.82. The data shows that as of 2024-12-31 short interest in Moderna Inc (MRNA) stood at 1294.0 of shares outstanding, with shares short falling to 40.84 million registered in 2024-11-29. Current price change has pushed the stock -19.19% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the MRNA stock continues to rise going into the next quarter.
